 |
EPAS™ Solubilization Platform
Particle Engineering Technology for Poorly Soluble Compounds
PharmaForm’s EPAS™ (Evaporative Precipitation into Aqueous Solution) solubilization platform offers a powerful strategy for overcoming solubility challenges and accelerating drug product development. EPAS™ is a particle engineering technology that produces nanostructured particles with properties of high surface areas, rapid dissolution, improved physical stability, and enhanced bioavailability compared to conventional formulation technologies. Targeted to Biopharmaceutics Classification System (BCS) Class II compounds, EPAS™ is designed to transform poorly water-soluble drugs into stable nanostructured particles without physical milling or grinding procedures.
The ability to engineer stable particles with high dissolution rates and improved bioavailability with EPAS™ presents new opportunities in the development of commercial formulations for poorly water soluble drugs.
Key Benefits:
- Improved patient compliance
- Improved clinical profiles
- Reduced dose variability
- Extended patent life and product differentiation
EPAS engineered particles can be formulated into various dosage forms, including solid oral, liquid, pulmonary and transdermal. EPAS uses conventional equipment that can be directly incorporated into a continuous manufacturing process. The process produces low levels of residual solvent and batches can be produced from pilot to commercial scale avoiding batch-to-batch variations. The EPAS platform is fast, continuous, and scalable providing for an economical manufacturing process.
EPAS Engineered Particles Features:
- Particle size in the range of nanometer to low micron size
- Control of particle size
- Narrow particle size distribution
- High surface area improves dissolution rate
- Enhanced bioavailability
- High drug loadings
- Stabilized to prevent agglomeration and particle growth
Click Here to download the EPAS Data Sheet
Contact Us
If you would like more information about EPAS or would like to perform a feasibility study using EPAS, click here or contact Elizabeth Hickman at 512 834-0449 x264.
<< back
|
